Vor Biopharma Inc’s recently made public that its 10% Owner Reprogrammed Interchange LLC unloaded Company’s shares for reported $2.55 million on Oct 08 ’25. In the deal valued at $33.87 per share,75,262 shares were sold. As a result of this transaction, Reprogrammed Interchange LLC now holds 1,423,659 shares worth roughly $43.86 million.
Then, Reprogrammed Interchange LLC sold 48,884 shares, generating $1,567,611 in total proceeds. Upon selling the shares at $32.07, the 10% Owner now owns 1,374,775 shares.
Before that, Reprogrammed Interchange LLC sold 70,763 shares. Vor Biopharma Inc shares valued at $2,618,788 were divested by the 10% Owner at a price of $37.01 per share. As a result of the transaction, Reprogrammed Interchange LLC now holds 1,526,545 shares, worth roughly $47.03 million.
Stifel upgraded its Vor Biopharma Inc [VOR] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late June from “a Neutral” to “a Buy”. Wedbush began covering VOR with “an Outperform” recommendation on July 26, 2022. Goldman started covering the stock on April 27, 2022. It rated VOR as “a Neutral”.
Price Performance Review of VOR
On Tuesday, Vor Biopharma Inc [NASDAQ:VOR] saw its stock fall -4.58% to $30.81. Over the last five days, the stock has lost -8.85%. Vor Biopharma Inc shares have risen nearly 135.30% since the year began. Nevertheless, the stocks have risen 38.78% over the past one year.
How much short interest is there in Vor Biopharma Inc?
A steep rise in short interest was recorded in Vor Biopharma Inc stocks on 2025-09-30, growing by 0.36 million shares to a total of 1.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 0.99 million shares. There was a rise of 26.57%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 17, 2021 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $26 price target.
